FirstWord

EPI-321 improved muscle volume, and strength, in patients with facioscapulohumeral muscular dystrophy.

Partner Eli Lilly plans to participate in the offering.

The deal centres on an investigational GCase enzyme replacement therapy enabled by Alector’s proprietary blood-brain barrier delivery platform.

Molecular gates are oral small molecules capable of eliminating difficult-to-drug proteins by selectively their progress through the secretory channel.

Vaxcyte's VAX-31 demonstrated non-inferiority to Pfizer's 20-valent pneumococcal vaccine Prevnar 20 and Merck & Co.'s 21-valent pneumococcal shot Capvaxive.

On the heels of two-year data on Johnson & Johnson's Icotyde (icotrokinra) presented at the European Academy of Dermatology and Venereology (EADV) Congress and six months after its US approval, FirstWord is polling physicians to find out whether the early hype around the oral IL-23–inhibiting pe

The Board of Directors (the ‘‘Board’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company’’, together with its subsidiaries, the ‘‘Group’’) is pleased to announce that the Group will present the late...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevib...

IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephr...

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i...